Le Lézard1d
InMode Reports Fourth Quarter and Full Year 2024 Financial Results; Board of Directors Has Approved a New Share Repurchase Program
On February 3rd, our Board of Directors approved another tax-efficient share repurchase program of up to 10% of our total shares outstanding, expected to be executed over the next three to six months.
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of ...
The Armenian Reporter1d
Insider Buying: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Acquires 14,562 Shares of Stock
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) major shareholder Venrock Healthcare Capital Par bought 14,562 shares of the firm’s stock in a transaction on Monday, February 3rd. The ...
KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded at Citizens Jmp
Citizens Jmp upgraded shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) to a strong-buy rating in a report ...
Fintel on MSN4d
JMP Securities Initiates Coverage of KalVista Pharmaceuticals (KALV) with Market Outperform Recommendation
Fintel reports that on January 31, 2025, JMP Securities initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a ...
JMP reiterates Kalvista stock with $19 target, sees market growth
JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...
KalVista initiated with an Outperform at JMP Securities
JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a ...
Optimistic Buy Rating for KalVista Pharmaceuticals Amid Promising Launch of Sebetralstat
Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...